G 
Guangzhou LBP Medicine Science & Technology Co 688393.SS · CNY
Health Care · Shanghai · 🇨🇳 China
17.40
-1.42%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥347.3m
FY2016FY2025
Net income
−CN¥45.0m
FY2016FY2025
Free cash flow
CN¥16.9m
FY2016FY2025
Shareholders' equity
CN¥1.18bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥347.3m | CN¥470.8m | CN¥497.3m | CN¥507.4m | CN¥439.0m | CN¥375.4m | CN¥355.2m | CN¥306.3m | CN¥260.5m | CN¥241.2m |
| Research and development | CN¥36.1m | CN¥45.5m | CN¥62.7m | CN¥67.4m | CN¥45.9m | CN¥27.7m | CN¥21.9m | CN¥15.6m | CN¥15.3m | CN¥13.3m |
| Operating income | −CN¥51.9m | CN¥11.0m | CN¥21.5m | CN¥28.7m | CN¥88.9m | CN¥100.2m | CN¥88.8m | CN¥74.4m | CN¥60.6m | CN¥47.0m |
| Net income | −CN¥45.0m | CN¥21.3m | CN¥40.1m | CN¥42.7m | CN¥79.8m | CN¥84.7m | CN¥74.0m | CN¥61.5m | CN¥48.3m | CN¥46.0m |
| Diluted earnings per share | -0.43 | 0.23 | 0.40 | 0.46 | 0.83 | 0.92 | 1.07 | 0.58 | 0.46 | 0.44 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥1.29bn | CN¥1.36bn | CN¥1.40bn | CN¥1.39bn | CN¥1.37bn | CN¥1.29bn | CN¥538.0m | CN¥476.6m | CN¥412.1m | CN¥357.0m |
| Cash and short-term investments | — | CN¥150.5m | CN¥120.2m | CN¥266.4m | CN¥637.1m | CN¥845.7m | CN¥170.6m | CN¥75.0m | CN¥73.7m | CN¥96.1m |
| Total liabilities | CN¥128.0m | CN¥131.0m | CN¥161.6m | CN¥170.4m | CN¥156.0m | CN¥124.7m | CN¥93.3m | CN¥87.2m | CN¥65.8m | CN¥36.1m |
| Debt | — | CN¥8.9m | CN¥31.8m | CN¥24.8m | CN¥12.4m | CN¥1.8m | — | — | — | — |
| Shareholders' equity | CN¥1.18bn | CN¥1.26bn | CN¥1.26bn | CN¥1.23bn | CN¥1.20bn | CN¥1.17bn | CN¥443.3m | CN¥386.8m | CN¥342.8m | CN¥315.5m |
| Shares outstanding | 106m | 92m | 100m | 93m | 96m | 92m | 69m | 106m | 106m | 106m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥40.0m | CN¥3.5m | CN¥17.1m | CN¥9.7m | CN¥59.6m | CN¥91.4m | CN¥89.7m | CN¥65.4m | CN¥83.9m | CN¥43.4m |
| Capital spending | −CN¥23.2m | −CN¥23.6m | −CN¥37.7m | −CN¥72.2m | −CN¥143.3m | −CN¥62.4m | −CN¥35.5m | −CN¥43.9m | −CN¥33.4m | −CN¥15.8m |
| Free cash flow | CN¥16.9m | −CN¥20.1m | −CN¥20.6m | −CN¥62.5m | −CN¥83.7m | CN¥29.0m | CN¥54.2m | CN¥21.4m | CN¥50.5m | CN¥27.6m |
| Dividends paid | −CN¥9.5m | −CN¥14.5m | −CN¥13.5m | −CN¥25.2m | −CN¥26.1m | — | −CN¥17.5m | −CN¥16.5m | −CN¥21.0m | −CN¥9.8m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥92.0m | CN¥79.6m | CN¥94.3m | CN¥93.5m | CN¥86.9m | CN¥72.5m | CN¥118.1m | CN¥124.6m |
| Operating income | CN¥3.5m | −CN¥3.4m | −CN¥36.3m | CN¥1.8m | −CN¥2.9m | −CN¥14.5m | −CN¥10.5m | CN¥13.2m |
| Net income | CN¥2.6m | −CN¥1.8m | −CN¥34.2m | CN¥1.7m | −CN¥1.4m | −CN¥11.1m | −CN¥8.3m | CN¥13.3m |
| Diluted earnings per share | 0.02 | -0.02 | -0.32 | 0.02 | -0.01 | -0.10 | -0.09 | 0.14 |
| Cash from operations | — | — | — | CN¥29.0m | CN¥15.0m | CN¥3.0m | — | CN¥15.0m |
| Capital spending | −CN¥8.0m | −CN¥5.0m | — | −CN¥12.0m | −CN¥6.0m | −CN¥5.0m | −CN¥8.0m | −CN¥8.0m |
| Free cash flow | — | — | — | CN¥17.0m | CN¥9.0m | −CN¥2.0m | — | CN¥7.0m |
| Total assets | CN¥1.25bn | CN¥1.26bn | CN¥1.29bn | CN¥1.31bn | CN¥1.33bn | CN¥1.33bn | CN¥1.36bn | CN¥1.38bn |
| Cash and short-term investments | — | — | — | CN¥264.2m | CN¥164.7m | CN¥96.5m | CN¥150.5m | CN¥110.0m |
| Debt | — | — | — | CN¥13.3m | CN¥14.8m | CN¥2.1m | CN¥7.3m | CN¥7.0m |
| Shareholders' equity | CN¥1.14bn | CN¥1.18bn | CN¥1.18bn | CN¥1.23bn | CN¥1.23bn | CN¥1.25bn | CN¥1.26bn | CN¥1.27bn |
Financial ratios
Data as of 26 Oct 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2013 | |
|---|---|---|---|---|---|---|---|
| Operating margin | -16.1% | 2.2% | 3.6% | 5.9% | 20.3% | 26.6% | — |
| Net margin | -13.0% | 4.5% | 8.1% | 8.4% | 18.2% | 22.6% | — |
| Return on equity | -3.8% | 1.7% | 3.2% | 3.5% | 6.6% | 7.3% | — |
| Return on assets | -3.5% | 1.6% | 2.9% | 3.1% | 5.8% | 6.6% | — |
| Free cash flow yield | 3.1% | 1.5% | 2.8% | 4.5% | 10.9% | 8.6% | — |
| Revenue growth | -26.2% | -5.3% | -2.0% | 15.6% | 16.9% | 5.7% | — |
| Earnings growth | -311.2% | -46.8% | -6.2% | -46.5% | -5.9% | 14.5% | — |
| Current ratio | 7.34x | 8.19x | 5.14x | 5.21x | 8.51x | 12.16x | — |
| Debt to equity | — | 0.01x | 0.02x | 0.01x | 0.01x | — | 0.05x |
| Equity ratio | 92.0% | 92.1% | 90.3% | 88.2% | 88.2% | 90.4% | — |
| Interest coverage | -171.34x | 12.04x | 21.85x | 22.19x | 169.73x | 1354.63x | — |
| R&D as a share of sales | 10.4% | 9.7% | 12.6% | 13.3% | 10.5% | 7.4% | — |
| Buybacks as a share of market value | -14.2% | 7.1% | -7.4% | 3.5% | -4.1% | -33.5% | — |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | -11.9% | -1.5% | 9.3% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | -5.0% | 0.5% | 7.5% | 12.9% |
| Net margin | -2.9% | 3.2% | 8.5% | 12.5% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Price to earnings | -55.6 | 75.2 | 62.0 | 47.8 | 36.7 | 40.2 |
| Price to sales | 7.2 | 3.4 | 5.0 | 4.0 | 6.7 | 9.1 |
Dividends and splits
Per share, in the currency the company pays
Paid for 5 years. Last went ex-dividend on 3 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Paid in the year | 0.10 | 0.10 | 0.15 | 0.14 | 0.27 | 0.28 |
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.